William Douglas Figg Sr.
#106,189
Most Influential Person Now
American pharmacologist
William Douglas Figg Sr.'s AcademicInfluence.com Rankings
William Douglas Figg Sr.medical Degrees
Medical
#1341
World Rank
#1668
Historical Rank
#368
USA Rank
Pharmacology
#106
World Rank
#135
Historical Rank
#26
USA Rank
Download Badge
Medical
Why Is William Douglas Figg Sr. Influential?
(Suggest an Edit or Addition)According to Wikipedia, William Douglas Figg is an American scientist . He is a senior investigator at the National Cancer Institute , National Institutes of Health , Bethesda, Maryland. He holds multiple titles within the NCI: Associate Director of the Center for Cancer Research, Co-Director of the Office of Translational Resources, Acting Branch Chief for the Genitourinary Malignancies Branch, Chief of the Clinical Pharmacology Program, and head of the Molecular Pharmacology Section. Dr. Figg is also the Co-Chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National Military Medical Center – Murtha Cancer Center in Bethesda, Maryland.
William Douglas Figg Sr.'s Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. (1999) (1024)
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. (2009) (668)
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. (2017) (546)
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. (2002) (540)
- Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015) (496)
- Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. (2000) (458)
- Angiogenesis Inhibitors: Current Strategies and Future Prospects (2010) (443)
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. (2011) (426)
- Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. (2000) (420)
- Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) (2005) (413)
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. (1998) (404)
- Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. (1996) (397)
- Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. (2005) (381)
- Herbal remedies in the United States: potential adverse interactions with anticancer agents. (2004) (373)
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. (2004) (360)
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. (2008) (322)
- Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. (2001) (315)
- A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. (2001) (311)
- Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo (2007) (308)
- Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. (2006) (301)
- Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. (1998) (299)
- Activity of thalidomide in AIDS-related Kaposi's sarcoma. (2000) (286)
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. (2007) (273)
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. (2015) (259)
- 2‐Methoxyestradiol, a Promising Anticancer Agent (2003) (251)
- Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. (2006) (243)
- Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review (2005) (235)
- Selumetinib in Children with Inoperable Plexiform Neurofibromas. (2020) (231)
- Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. (2003) (222)
- Scientific Collaboration Results in Higher Citation Rates of Published Articles (2006) (221)
- A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. (2001) (217)
- Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. (1998) (217)
- Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura (2006) (215)
- Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation (2009) (207)
- Validation of Analytic Methods for Biomarkers Used in Drug Development (2008) (207)
- Drug interactions in cancer therapy (2006) (204)
- Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel (2008) (204)
- A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. (2002) (201)
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors (2010) (198)
- Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy (2005) (184)
- Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer (2008) (184)
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. (2017) (182)
- Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. (2004) (181)
- Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. (2003) (175)
- Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. (1995) (175)
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer (2008) (175)
- Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? (2001) (175)
- Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. (2014) (171)
- Pharmacogenetics of irinotecan metabolism and transport: an update. (2006) (170)
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors (2012) (170)
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors (2009) (170)
- Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2009) (168)
- Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. (2006) (164)
- A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. (1994) (162)
- A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer (2012) (158)
- Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. (2001) (157)
- Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. (2008) (156)
- Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics (2007) (155)
- Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. (1998) (155)
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2002) (155)
- SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. (2011) (154)
- Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention (2006) (154)
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. (2011) (153)
- Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. (2002) (153)
- Antibody–drug conjugates for cancer (2019) (152)
- A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. (1996) (151)
- Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma (2013) (148)
- Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents (2009) (147)
- Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib (2006) (147)
- Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. (1999) (145)
- Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination (2005) (145)
- A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer (2010) (145)
- Thalidomide metabolism by the CYP2C subfamily. (2002) (143)
- Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1α (HIF-1α) and p300 by a Zinc Ejection Mechanism* (2009) (142)
- Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. (2004) (142)
- Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. (2001) (141)
- A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer (1998) (141)
- Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. (2010) (140)
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel (2008) (137)
- Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. (1994) (137)
- The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response (2013) (137)
- Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. (2004) (135)
- Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. (2008) (132)
- Phase I study of phenylacetate administered twice daily to patients with cancer (1995) (132)
- Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. (2002) (131)
- A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. (2001) (129)
- TNP-470: an angiogenesis inhibitor in clinical development for cancer (2000) (128)
- Multiparametric MRI in prostate cancer management (2014) (128)
- The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy (2001) (127)
- Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies (2007) (127)
- Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. (2008) (126)
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy (2009) (125)
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy (2010) (122)
- Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. (2005) (122)
- The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. (2000) (122)
- Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. (2005) (121)
- Population pharmacokinetic analysis of sorafenib in patients with solid tumours. (2011) (121)
- A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. (2013) (120)
- A Working Group Classification of Focal Prostate Atrophy Lesions (2006) (118)
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. (2010) (118)
- Pharmacogenetics of Membrane Transporters: An Update on Current Approaches (2010) (117)
- Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development (2002) (116)
- Modulation of cytochrome P450 activity: implications for cancer therapy. (2005) (115)
- Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. (2001) (115)
- Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38 (2004) (114)
- A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. (2000) (114)
- Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin (2007) (114)
- A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas (2011) (113)
- Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. (2005) (113)
- Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer (2009) (113)
- Drug interactions in cancer therapy (2006) (113)
- Pharmacokinetics of thalidomide in an elderly prostate cancer population. (1999) (112)
- Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. (1996) (110)
- A retrospective study of the time to clinical endpoints for advanced prostate cancer (2005) (108)
- Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. (2018) (108)
- Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression (2011) (107)
- Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. (2002) (107)
- Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia (2012) (106)
- Thalidomide (2022) (106)
- Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. (2011) (105)
- Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers (2011) (103)
- Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. (2000) (103)
- Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors (2011) (101)
- Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2001) (100)
- Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis (1997) (100)
- The androgen receptor gene and its influence on the development and progression of prostate cancer (2001) (100)
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib (2010) (99)
- Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. (1998) (99)
- CYP2D6 polymorphisms and the impact on tamoxifen therapy. (2007) (99)
- Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology (2005) (98)
- A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. (1999) (97)
- Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. (2000) (96)
- Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer (2002) (93)
- Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia (2005) (92)
- Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. (2000) (90)
- Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. (2007) (88)
- Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. (2004) (87)
- Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. (2008) (87)
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. (1995) (86)
- Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. (2003) (86)
- Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 (2004) (85)
- Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. (2001) (84)
- Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. (2010) (84)
- Thalidomide neuropathy in patients treated for metastatic prostate cancer (2001) (83)
- In vivo models of prostate cancer metastasis to bone. (2005) (83)
- COVID‐19 Clinical Diagnostics and Testing Technology (2020) (82)
- Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel (2008) (82)
- A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis (1998) (81)
- Apoptosis: Its Role in the Development of Malignancies and its Potential as a Novel Therapeutic Target (1997) (81)
- Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. (1997) (80)
- A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. (2005) (79)
- A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform (2010) (79)
- Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases (2018) (77)
- Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer (2016) (76)
- Precision Oncology Medicine: The Clinical Relevance of Patient‐Specific Biomarkers Used to Optimize Cancer Treatment (2016) (76)
- Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy (2005) (75)
- Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. (1994) (75)
- Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. (2003) (74)
- A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar) (2001) (74)
- Thalidomide metabolism and hydrolysis: mechanisms and implications. (2006) (74)
- Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables (1995) (73)
- Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients (2005) (73)
- Reversal of multidrug resistance: lessons from clinical oncology. (2002) (73)
- A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study (2014) (72)
- Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel (2006) (72)
- The CYP2C19*17 variant is not independently associated with clopidogrel response (2013) (72)
- The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma (2019) (71)
- Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel (2006) (71)
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma (2010) (70)
- Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer (2004) (69)
- Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. (2013) (69)
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses (2019) (69)
- Suramin's Development: What Did we Learn? (2002) (68)
- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. (2005) (68)
- A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma (2004) (67)
- Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. (2016) (67)
- Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. (2001) (66)
- Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma (2009) (66)
- Angiogenesis : an integrative approach from science to medicine (2008) (66)
- Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics (2007) (66)
- Thalidomide analogues as anticancer drugs. (2007) (66)
- Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine (1995) (65)
- Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (2017) (65)
- Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro (2013) (64)
- Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer (2019) (64)
- Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. (2004) (63)
- The control of prostate-specific antigen expression and gene regulation by pharmacological agents. (2001) (63)
- The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. (2002) (63)
- A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors (2007) (61)
- Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. (1995) (61)
- Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer (2014) (61)
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors (2020) (60)
- The Pharmacokinetics of TNP‐470, a New Angiogenesis Inhibitor (1997) (60)
- IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion (2019) (60)
- Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. (2012) (60)
- Integrating pharmacogenetic information and clinical decision support into the electronic health record (2014) (60)
- Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. (1995) (60)
- A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer (2008) (59)
- Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. (2000) (59)
- Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies (2013) (58)
- TMPRSS2: Potential Biomarker for COVID‐19 Outcomes (2020) (58)
- A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. (1999) (58)
- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer (2014) (57)
- A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. (2001) (57)
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms (2011) (56)
- Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers (2013) (56)
- Matrix Metalloproteinase Inhibitors: Do They Have a Place in Anticancer Therapy? (2002) (56)
- Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. (2008) (56)
- Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. (2014) (55)
- Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9 (2015) (55)
- Taxane-Mediated Antiangiogenesis in Vitro (2004) (55)
- Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. (2021) (55)
- Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (2004) (54)
- Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin (1997) (53)
- Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer (2009) (53)
- Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients (2010) (52)
- Approaches to preclinical screening of antiangiogenic agents. (2001) (52)
- Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. (1996) (51)
- Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. (1999) (51)
- Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology (2017) (50)
- Disclosing a diagnosis of cancer: where and how does it occur? (2010) (50)
- Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. (2008) (50)
- Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice (2004) (49)
- A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. (2012) (48)
- Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer (2016) (48)
- Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study (2011) (48)
- A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer (2015) (48)
- The androgen receptor: genetic considerations in the development and treatment of prostate cancer (1999) (48)
- Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates (2019) (48)
- Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. (2004) (48)
- 5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis (2002) (47)
- Dual Targeting of the Androgen Receptor and Hypoxia-Inducible Factor 1α Pathways Synergistically Inhibits Castration-Resistant Prostate Cancer Cells (2015) (47)
- Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer (2013) (47)
- Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. (2003) (47)
- Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. (2003) (47)
- Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis (1999) (47)
- Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. (2015) (47)
- Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation (2010) (47)
- A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer (2010) (46)
- Pre‐clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen‐independent prostate cancer (2007) (46)
- Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion (2003) (46)
- Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. (2010) (46)
- Statin drug use is not associated with prostate cancer risk in men who are regularly screened. (2014) (45)
- A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript (2017) (45)
- Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population (2018) (45)
- Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer (2009) (44)
- Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. (2003) (43)
- Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel (2013) (43)
- Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients (1997) (43)
- Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer (2003) (42)
- Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. (2020) (42)
- Methods for extracting and amplifying genomic DNA isolated from frozen serum (1998) (42)
- A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone‐refractory prostate cancer (1995) (42)
- Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance (2008) (42)
- Recent advances in pharmacogenetic approaches to anticancer drug development (2004) (42)
- A Phase II Clinical Trial of TRC105 (Anti‐Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma (2017) (41)
- Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. (2003) (41)
- A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response (1996) (41)
- The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma (2018) (40)
- Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model (2016) (40)
- Genetic variation: effect on prostate cancer. (2014) (40)
- Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency (1996) (40)
- Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism (2011) (39)
- Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer (2016) (39)
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. (2009) (39)
- Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. (1995) (39)
- A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib (2015) (38)
- Androgen receptor variation affects prostate cancer progression and drug resistance. (2016) (38)
- Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells (1999) (38)
- HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer (2018) (38)
- The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. (2001) (38)
- Comparison of Quantitative Methods to Assess Hepatic Function: Pugh's Classification, Indocyanine Green, Antipyrine, and Dextromethorphan (1995) (38)
- Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. (2017) (38)
- UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response (1998) (38)
- Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology (2014) (38)
- Resistance to second-generation androgen receptor antagonists in prostate cancer (2021) (38)
- Drug-induced lupus associated with COL-3: report of 3 cases. (2001) (38)
- Pharmacogenetics of membrane transporters: a review of current approaches. (2008) (37)
- Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor (2006) (37)
- Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1 (2008) (37)
- New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12 (2004) (37)
- Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. (2000) (37)
- Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. (2007) (37)
- Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma (2007) (36)
- A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors (2014) (36)
- Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. (2002) (36)
- Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor (1999) (36)
- Are sex discordant outcomes in COVID-19 related to sex hormones? (2020) (35)
- Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction. (2016) (35)
- Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers (2014) (35)
- Selective leukemic-cell killing by a novel functional class of thalidomide analogs. (2006) (35)
- Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. (2007) (35)
- Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs (2005) (35)
- Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. (2004) (34)
- Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma (2016) (34)
- Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures (2012) (34)
- Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. (2000) (34)
- Using Epigenetic Therapy to Overcome Chemotherapy Resistance. (2016) (34)
- Lack of Association Between Excretion of Sorafenib in Sweat and Hand‐Foot Skin Reaction (2010) (34)
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. (2008) (34)
- PARP Inhibitors & Prostate Cancer: To Infinity and Beyond BRCA. (2020) (34)
- A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. (2004) (33)
- Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. (2004) (33)
- Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer (2017) (32)
- Pharmacokinetic Studies with Recombinant Cytokines (1997) (32)
- Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). (2015) (32)
- Acute renal toxicity associated with suramin in the treatment of prostate cancer (1994) (32)
- Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutarimide. A metabolite of thalidomide isolated from human plasma. (2005) (32)
- Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. (2003) (31)
- In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems (2016) (31)
- Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2013) (31)
- Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. (1997) (31)
- A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. (2010) (31)
- Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial (2018) (31)
- A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors (2013) (30)
- A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. (1996) (30)
- Alteration in Indinavir Clearance During Interleukin‐2 Infusions in Patients Infected with the Human Immunodeficiency Virus (1998) (30)
- Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. (2005) (29)
- Thalidomide, an antiangiogenic agent with clinical activity in cancer. (2002) (29)
- A FACILE SCHEME FOR PHTHALIMIDE PHTHALIMIDINE CONVERSION (1999) (29)
- Current status of thalidomide and its role in the treatment of metastatic prostate cancer. (2003) (29)
- The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. (2011) (29)
- OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition (2012) (29)
- Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung (2018) (29)
- A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum (1997) (28)
- Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2015) (28)
- The differentiating agent phenylacetate increases prostate‐specific antigen production by prostate cancer cells (1996) (28)
- Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy (2013) (28)
- Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma (2019) (28)
- Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. (2001) (28)
- Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. (1999) (28)
- Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. (2003) (28)
- Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms (2003) (28)
- A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) (2007) (28)
- Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers (2008) (28)
- Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48‐hour continuous infusion in patients with cancer (2016) (27)
- Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival (2008) (27)
- Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. (2012) (27)
- A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas (2009) (27)
- Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance (2014) (27)
- Secondary hormonal therapy for prostate cancer: what lies on the horizon? (2008) (26)
- Pharmacogenetics of estrogen metabolism and transport in relation to cancer. (2003) (26)
- BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer (2014) (26)
- The Role of MRI in Prostate Cancer Active Surveillance (2014) (26)
- Detection of bladder, breast and prostate cancer using serum and tissue miRNA profiling (2011) (26)
- Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. (2012) (26)
- Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma (2006) (26)
- Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100 (2008) (26)
- Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. (2004) (26)
- Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α. (2015) (26)
- Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial (2016) (25)
- Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. (2003) (25)
- A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). (2014) (25)
- Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. (2014) (25)
- A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. (2019) (25)
- CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer (2015) (25)
- Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues (2015) (25)
- Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine (2004) (25)
- Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia (2011) (25)
- Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. (2006) (25)
- A phase II study of bromocriptine in patients with androgen-independent prostate cancer. (1998) (25)
- Sarcosine as a potential prostate cancer biomarker and therapeutic target (2010) (24)
- A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. (2015) (24)
- The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. (2003) (24)
- Mechanisms of Disease: polymorphisms of androgen regulatory genes in the development of prostate cancer (2005) (24)
- The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor (2010) (24)
- Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. (2001) (23)
- Pharmacogenomics and histone deacetylase inhibitors. (2016) (23)
- Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice (2009) (23)
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms (2014) (23)
- Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience (2010) (23)
- Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells (2015) (23)
- Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. (1998) (23)
- Impact of ABCB1 Allelic Variants on QTc Interval Prolongation (2010) (23)
- Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer (2016) (22)
- Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3 (2001) (22)
- Treatment options for androgen-independent prostate cancer. (2003) (22)
- Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients (2008) (22)
- Determination of fraction unbound docetaxel using microequilibrium dialysis. (2004) (22)
- A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application (2014) (22)
- Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. (2016) (22)
- The Mutated Androgen Receptor and Its Implications for the Treatment of Metastatic Carcinoma of the Prostate (1996) (22)
- Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial (2010) (22)
- Tocilizumab in Patients with Symptomatic Kaposi sarcoma Herpesvirus (KSHV)- associated Multicentric Castleman disease. (2020) (22)
- ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment (2016) (21)
- Initial Pharmacokinetics and Bioavailability of PSC 833, a P‐Glycoprotein Antagonist (1997) (21)
- Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. (2001) (21)
- The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer (2002) (21)
- Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. (2017) (21)
- Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? (2005) (21)
- Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial (2016) (21)
- Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease (2016) (21)
- A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. (2003) (21)
- High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. (2000) (21)
- Reviewing the role of healthy volunteer studies in drug development (2018) (21)
- Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. (2001) (21)
- Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models (2009) (21)
- Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction. (1995) (20)
- Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer (2006) (20)
- Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. (2004) (20)
- Pharmacy Education: Back to the Basics? (2003) (20)
- A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. (2014) (20)
- Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model (2008) (20)
- Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. (2013) (20)
- Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors (2018) (20)
- Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques (2018) (20)
- Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. (2011) (20)
- Pharmacokinetics of Intravenous Voriconazole in Obese Patients: Implications of CYP2C19 Homozygous Poor Metabolizer Genotype (2013) (19)
- Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma. (1994) (19)
- Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies (2021) (19)
- More than an accessory: implications of type III transforming growth factor‐β receptor loss in prostate cancer (2010) (19)
- Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included). (2008) (19)
- Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches (2003) (19)
- Importance of the Stress Kinase p38α in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells (2006) (19)
- Mifepristone: antineoplastic studies. (1996) (19)
- Pharmacogenomics Implementation at the National Institutes of Health Clinical Center (2017) (19)
- A Preliminary Risk-Benefit Assessment of Paclitaxel (1995) (19)
- A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer (1999) (19)
- Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. (2008) (18)
- Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2 (2010) (18)
- A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma (2017) (18)
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer (2017) (18)
- ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer (2007) (18)
- Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC) (2008) (18)
- Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer. (1998) (18)
- Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC). (2016) (18)
- Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin (2020) (18)
- Effect of Common CYP 3 A 4 and CYP 3 A 5 Variants on the Pharmacokinetics of the Cytochrome P 450 3 A Phenotyping ProbeMidazolam in Cancer Patients (2005) (18)
- A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer. (2016) (18)
- Prostate cancer progression attributed to autonomic nerve development (2013) (18)
- The Genetics of Castration-Resistant Prostate Cancer: What Can the Germline Tell Us? (2008) (18)
- A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. (2000) (17)
- Pharm.D. Pathways to Biomedical Research: The National Institutes of Health Special Conference on Pharmacy Research (2008) (17)
- Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. (2014) (17)
- Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy (2011) (17)
- Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy (2019) (17)
- Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer (2014) (17)
- Drug management of prostate cancer (2010) (17)
- Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters (2019) (17)
- Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism. (2004) (17)
- Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. (2006) (17)
- Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors (2015) (16)
- Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial (2018) (16)
- The ABCG2 Multidrug Transporter (2016) (16)
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly (2007) (16)
- In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. (1997) (16)
- A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer (2003) (16)
- A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms (2014) (16)
- Combinatorial Antileukemic Disruption of Oxidative Homeostasis and Mitochondrial Stability by the Redox Reactive Thalidomide 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and Flavopiridol (2008) (16)
- UGT1A1 genotype‐dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation (2016) (16)
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. (2017) (15)
- Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC) (2008) (15)
- Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities (2014) (15)
- Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx (2017) (15)
- Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer (2004) (15)
- Hormone-refractory prostate cancer: where are we going? (2007) (15)
- The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. (2016) (15)
- Ondansetron: a novel antiemetic agent. (1993) (15)
- Malignant ascites as only manifestation of metastatic prostate cancer (1999) (15)
- Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. (2013) (15)
- Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors (2020) (15)
- The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap. (1995) (14)
- A phase I / II study of sepantronium bromide ( YM 155 , survivin suppressor ) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer (2013) (14)
- Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. (1996) (14)
- Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. (2010) (14)
- Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis. (2008) (14)
- Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models (2019) (14)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (14)
- Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride (2012) (14)
- Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder (2004) (14)
- Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma (2021) (14)
- Factors Involved in the Pharmacokinetics of COL‐3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies (2003) (14)
- Angiogenesis and prostate cancer: Important laboratory and clinical findings (2005) (14)
- The use of thalidomide in androgen-independent prostate cancer. (2006) (14)
- A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer. (2017) (14)
- In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. (1994) (13)
- Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk (2019) (13)
- Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro (2020) (13)
- Angiogenesis inhibitors in the treatment of prostate cancer (2010) (13)
- Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. (2004) (13)
- Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activities. (2018) (13)
- Comparative study of the clinical efficacy of two dosing regimens of flutamide. (1999) (13)
- Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. (2005) (13)
- Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. (2006) (13)
- Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models (2018) (13)
- Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-γ-hydroxyglutamic acid (2000) (13)
- Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine (2000) (13)
- Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. (2015) (12)
- Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura. (2002) (12)
- First-in-human phase 0 study of 111In-CHX-A”-DTPA trastuzumab for HER2 tumor imaging (2018) (12)
- Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. (2015) (12)
- Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. (1997) (12)
- Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model (2017) (12)
- A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma (2019) (12)
- Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study (2009) (12)
- Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics (2021) (12)
- New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology. (2003) (12)
- ABCB1 genetic variation influences the toxicity and clinical outcome of patients treated with docetaxel (2008) (12)
- 825: Follow-up Analysis of A Randomized Phase II Study of Docetaxel (D) and Thalidomide (T) in Androgen-Independent Prostate Cancer (AIPC): Updated Survival Data and Stratification by CYP2C19 Mutation Status (2005) (12)
- Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors (2019) (12)
- PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. (2019) (12)
- Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. (1996) (12)
- UGT genotyping in belinostat dosing. (2016) (11)
- Epigenetic approaches to overcoming chemotherapy resistance. (2015) (11)
- Contribution of the OATP1B Subfamily to Cancer Biology and Treatment (2012) (11)
- Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen (2020) (11)
- No rational theory for drug pricing. (2004) (11)
- Validation of Analytical Methods for Biomarkers Employed in Drug Development (2009) (11)
- Angiogenesis inhibitors increase tumor stem cells (2012) (11)
- Antiangiogenesis: a possible treatment option for prostate cancer? (2005) (11)
- National Cancer Institute intramural approach to advanced prostate cancer. (2002) (11)
- Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors (2021) (11)
- Precision medicine applications in prostate cancer (2018) (11)
- A randomized phase-2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease. (2020) (11)
- Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy. (1997) (11)
- Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma (1997) (11)
- Taxanes in hormone-refractory prostate cancer. (2001) (11)
- A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. (2018) (11)
- Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone (2017) (10)
- A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. (2019) (10)
- U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's health. (2009) (10)
- A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. (2013) (10)
- Thalidomide analogues: derivatives of an orphan drug with diverse biological activity (2004) (10)
- Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. (1996) (10)
- Peripheral Neuropathy in HIV Patient after Isoniazid Therapy Initiated (1991) (10)
- Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma (2020) (10)
- Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib (2008) (10)
- Pharmacogenetics of membrane transporters: a review of current approaches. (2014) (10)
- Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine (2014) (10)
- Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (10)
- The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen‐independent prostate cancer (2006) (10)
- Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry. (2006) (10)
- Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. (2009) (10)
- Multiplying therapies and reducing toxicity in metastatic melanoma (2015) (10)
- Vertebrate embryos as tools for anti-angiogenic drug screening and function. (2017) (10)
- The canSAR data hub for drug discovery. (2016) (10)
- A PHASE I TRIAL ADMINISTERING THE ANGIOGENESIS INHIBITOR TNP-470(AGM-1470) TO PATIENTS (PTS) WITH HIV-ASSOCIATED KAPOSI'S SARCOMA(KS): 13 (1997) (10)
- Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. (2013) (10)
- Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat (2021) (10)
- Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. (2006) (10)
- Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs (2020) (10)
- A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC). (2017) (9)
- Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer. (2006) (9)
- Synthesis of a stable and orally bioavailable englerin analogue. (2016) (9)
- Stem cell clinics: risk of proliferation. (2020) (9)
- Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one (1996) (9)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (9)
- Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay (2002) (9)
- Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. (2003) (9)
- Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. (2020) (9)
- Hormone-Refractory Prostate Cancer (2012) (9)
- Suramin-induced neutropenia. (1996) (9)
- Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. (2006) (9)
- Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study (2014) (9)
- A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer (2015) (9)
- Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system (2017) (9)
- Pharmacokinetics and Relative Bioavailability of Carboxyamido-Triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters (1998) (9)
- Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol (2006) (9)
- A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors (2009) (9)
- A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. (2013) (9)
- VEGF inhibition and metastasis: Possible implications for antiangiogenic therapy (2009) (9)
- Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (8)
- A Phase 1 First-in-Human Study of TRC 105 ( Anti-Endoglin Antibody ) in Patients with Advanced Cancer (2012) (8)
- Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain (2019) (8)
- Tariquidar (XR9576) is a potent and effective P-glycoprotein (Pgp) inhibitor that can be administered safely with chemotherapy (2005) (8)
- Leptomeningeal carcinomatosis in metastatic prostate cancer. (2002) (8)
- Antiangiogenesis Therapeutic Strategies in Prostate Cancer (2004) (8)
- Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers (2017) (8)
- A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting (2010) (8)
- PRELIMINARY RESULTS OF A PHASE II STUDY OF ORAL THALIDOMIDE IN PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA (KS): 20 (1997) (8)
- A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. (2002) (8)
- Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models (2021) (8)
- Routine interval computed tomography to detect new soft‐tissue disease might be unnecessary in patients with androgen‐independent prostate cancer and metastasis only to bone (2007) (8)
- A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). (2014) (8)
- Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. (2014) (8)
- Thalidomide Metabolism by the CYP 2 C Subfamily 1 (2002) (8)
- Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). (2013) (8)
- Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids (2016) (8)
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas (2021) (8)
- Aseptic Meningitis Associated with Muromonab-CD3 (1991) (8)
- A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid Chromatography (1994) (7)
- Reversal of docetaxel resistance with bevacizumab and thalidomide. (2009) (7)
- Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. (2016) (7)
- A phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms (1998) (7)
- Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. (2014) (7)
- Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma (2020) (7)
- Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs (2020) (7)
- Urinary osteopontin as a marker for localized and metastatic prostate cancer. (2011) (7)
- Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial. (2008) (7)
- Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses (2016) (7)
- Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management (2021) (7)
- Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures (2019) (7)
- Identifying Sources of Interindividual Pharmacokinetic Variability with Population Modeling (2006) (7)
- Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy (2008) (7)
- Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? (2013) (7)
- Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. (2019) (7)
- Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study (2020) (7)
- Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study (2020) (7)
- Uncovering the genetic landscape driving castration-resistant prostate cancer (2013) (7)
- Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p (2021) (7)
- Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway (2010) (7)
- Anaphylactoid Reaction With Suramin (1993) (7)
- Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma (2021) (7)
- Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer (2021) (6)
- Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. (2007) (6)
- Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. (2016) (6)
- Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. (2010) (6)
- Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer (2020) (6)
- Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos (2013) (6)
- On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. (2020) (6)
- Ibrutinib’s off-target mechanism: cause for dose optimization (2021) (6)
- Detectible mosaic truncating PPM1D mutations, age and breast cancer risk (2019) (6)
- The Use of Complementary and Alternative Medicine in Prostate Cancer Patients (2000) (6)
- Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab (2012) (6)
- Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. (1997) (6)
- Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy (2020) (6)
- A snP in CYP 2 C 8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer (2010) (6)
- Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma (2015) (6)
- HG-36PLASMA AND CEREBROSPINAL FLUID (CSF) PHARMACOKINETICS OF PANOBINOSTAT FOLLOWING ORAL ADMINISTRATION TO NONHUMAN PRIMATES (2016) (6)
- Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. (2010) (6)
- Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223? (2020) (6)
- Revisiting 5α-reductase inhibitors and the risk of prostate cancer (2018) (6)
- Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2 (2006) (6)
- The role of drug-metabolising enzymes in clinical responses to chemotherapy (2006) (6)
- Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. (2002) (6)
- Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8md00548f (2019) (6)
- Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer (2019) (6)
- A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models (2020) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study (2016) (6)
- Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. (1994) (6)
- Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib (2020) (6)
- A chiral pool approach toward the synthesis of thalidomide metabolites (2006) (6)
- Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). (2009) (5)
- A phase II trial of docetaxel (D), estramustine (E) and thalidomide (T) in patients with metastatic androgen-independent prostate cancer (AIPC) (2005) (5)
- Irinotecan in small-cell lung cancer. (2002) (5)
- Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors (2020) (5)
- Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression. (2014) (5)
- How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer (2012) (5)
- A Polymorphic Variant of AFAP-110 Enhances cSrc Activity. (2010) (5)
- PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide. (2020) (5)
- Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. (2019) (5)
- Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy (2022) (5)
- Significant addition to treatment options for bone metastasis in prostate cancer (2012) (5)
- CPS49‐induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos (2018) (5)
- Loss of OATP1B3 function causes Rotor syndrome (2012) (5)
- Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer. (2015) (5)
- Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. (2004) (5)
- Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion? (2016) (5)
- Cellular identity crisis: Antiandrogen resistance by lineage plasticity (2017) (5)
- Correlative studies of a phase I trial of combination anti-vascular endothelial growth factor (VEGF) therapy with sorafenib and bevacizumab (2008) (5)
- Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model. (2012) (5)
- An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC (1997) (5)
- Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. (2004) (5)
- Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. (2021) (5)
- A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer. (2016) (5)
- Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide (2019) (5)
- Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone) (2007) (5)
- Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw (2021) (5)
- A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC. (2010) (5)
- Adenosine A2A Receptor Activation Enhances Blood–Tumor Barrier Permeability in a Rodent Glioma Model (2021) (5)
- Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation (2021) (5)
- The Pharm.D. Investigator in Clinical Pharmacology: Supply and Demand (2008) (5)
- Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response (2009) (5)
- Are race-speci fi c ERCC 1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC 1 N 118 N ? (2013) (4)
- Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. (2016) (4)
- Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC) (2008) (4)
- Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. (2009) (4)
- Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. (2016) (4)
- Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. (2005) (4)
- Phase I trial of the oral histone deacetylase inhibitor MS-275 administered with food. (2006) (4)
- Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes (2020) (4)
- Antiangiogenesis therapeutic strategies in prostate cancer. (2002) (4)
- Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. (2017) (4)
- Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models. (2020) (4)
- Survivin is not induced by novel taxanes. (2010) (4)
- Private Practice Administrative Costs Influenced by Insurance Payer Mix. (2009) (4)
- Adaptive control with feedback of suramin using intermittent infusions. (1994) (4)
- A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. (2010) (4)
- Androgen receptor sequence and variations in several common prostate cancer cell lines (2010) (4)
- Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis (2008) (4)
- A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). (2006) (4)
- The androgen receptor transcriptional program in castration-resistant prostate cancer (2014) (4)
- Suramin administration is associated with a decrease in serum calcium levels (2000) (4)
- A phase II study of BAY 43–9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling (2005) (4)
- Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. (2021) (4)
- A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat (2018) (4)
- A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas (2020) (4)
- Lutetium-177-PSMA-617: A Vision of the Future (2022) (4)
- Building a hit list for the fight against metastatic castration resistant prostate cancer (2016) (4)
- Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects (2017) (4)
- A modeling and simulation study of less frequent dosing of nivolumab 480 mg. (2019) (4)
- A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer. (2020) (4)
- Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma (2020) (4)
- Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma (2022) (4)
- Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. (2012) (4)
- Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors? (2020) (4)
- Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648). (2014) (4)
- Preliminary results of a phase II study of oral thalidomide in patients with AIDS-related Kaposl's sarcoma (KS) (1998) (3)
- Evaluating immune responses after sipuleucel-T therapy (2015) (3)
- Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma (2021) (3)
- Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan. (2004) (3)
- Aflibercept in Pediatric Solid Tumors: Moving Beyond the Trap (2012) (3)
- A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer (2019) (3)
- Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides (2018) (3)
- Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation (2014) (3)
- Metronomic ABI-007 therapy: antiangiogenic and antitumor activity of a nanoparticle albumin-bound paclitaxel (2005) (3)
- A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases. (2020) (3)
- Translational proof of mechanism (PoM) for sorafenib with bevacizumab: Endpoint analysis and clinical activity. (2009) (3)
- A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy (2021) (3)
- Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis. (2018) (3)
- Routine interval computed tomography in detecting new soft tissue disease in patients with androgen-independent prostate cancer (AIPC) and only bone metastasis. (2006) (3)
- Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed? (2015) (3)
- Whole or Partial Vessel Outgrowth Assays (2007) (3)
- A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer. (2019) (3)
- Pentosan polysulfate: A Polysaccharide That inhibits Angiogenesis by Binding Growth Factors (1998) (3)
- Prolonged low intensity EPOCH–rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy (2014) (3)
- Pharmacometric Analysis of the Effect of Furosemide on Suramin Pharmacokinetics (1997) (3)
- Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (3)
- Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma. (1999) (3)
- Functional Drug Screening in the Era of Precision Medicine (2022) (3)
- Safety , efficacy , and pharmacokinetics / pharmacodynamics of daclizumab ( anti-CD 25 ) in patients with adult T-cell leukemia / lymphoma (2015) (3)
- Piecing together the HIF-1 puzzle: The role of the CTGF as a molecular mechanism of HIF-1 regulation (2006) (3)
- DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance (2014) (3)
- A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer. (2014) (3)
- Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. (2015) (3)
- Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms (2017) (3)
- An international genome-wide meta-analysis of bisphosphonate related osteonecrosis of the jaw (2019) (3)
- Genetic stability of tumor microenvironment (2008) (3)
- Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft (2012) (3)
- Cancer Therapy : Clinical Multihistology , Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 a in Advanced Solid Tumors (2011) (3)
- New tricks from an old drug: A role for quinacrine in anti-cancer therapy? (2009) (3)
- DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047) (2022) (3)
- Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer (2012) (3)
- shRNA technology: Investigating Ras-dependent cancer (2009) (3)
- Thalidomide Metabolites and Analogues. Part 2. Cyclic Derivatives of 2-N-Phthalimido-2S,3S(3-hydroxy)ornithine. (2000) (2)
- Mutated androgen receptors of prostate-cancer cells. (1995) (2)
- Potential novel role of bevacizumab in glioblastoma and cervical cancer (2014) (2)
- Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer. (2019) (2)
- A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. (2009) (2)
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up (2018) (2)
- Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation (2006) (2)
- Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors (2022) (2)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- Interim analysis of phase I trial of 17-DMAG. (2006) (2)
- Determination of the fraction unbound docetaxel using micro-equilibrium dialysis (2004) (2)
- Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. (2020) (2)
- Erratum: A working group classification of focal prostate atrophy lesions (American Journal of Surgical Pathology (2006) 30 (1281-1291)) (2006) (2)
- 390PA phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers (2017) (2)
- Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma. (2013) (2)
- Intermediate end point for survival for patients with hormone refractory metastatic prostate cancer (2005) (2)
- Anti-Cancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogs (2015) (2)
- DNA Topoisomerase Targeting Drugs (2017) (2)
- Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors (2021) (2)
- TRTH-33. COMPARATIVE PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF BRAF AND MEK INHIBITORS IN A NONHUMAN PRIMATE MODEL (2017) (2)
- Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). (2013) (2)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer. (2021) (2)
- Angiogenesis Inhibitors in Prostate Cancer (2006) (2)
- A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer 1 (1999) (2)
- ResearchHypertension and hand-foot skin reactions related to VEGFR 2 genotype and improved clinical outcome following bevacizumab and sorafenib (2015) (2)
- Ondansetron versus dexamethasone (1991) (2)
- Author response: Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates (2019) (2)
- Insulin potentiation therapy for cancer? (2019) (2)
- Reply to C. Nabhan et al (2011) (2)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors. (2021) (2)
- Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer. (2022) (2)
- New mechanism of lenalidomide activity (2014) (2)
- Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer (2020) (2)
- A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC). (2019) (2)
- Preliminary Pharmacokinetics (PK) of COL‐3, A Matrix Metalloproteinase (MMP) Inhibitor (1999) (2)
- Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. (2021) (2)
- Principles of Antiangiogenic Therapy (2010) (2)
- Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients (2017) (2)
- Percutaneous hepatic perfusion with melphalan for unresectable liver metastasis (2016) (2)
- A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2014) (2)
- Dose Optimization of Pembrolizumab: Less May Be More (2021) (2)
- Androgen synthesis and steroid transporters in prostate cancer: Rethinking the transition to CRPC (2010) (2)
- BETting on next-generation bromodomain inhibitors. (2020) (2)
- Prolonged response to flutamide withdrawal and initiation of aminoglutethimide in a patient with metastatic prostate cancer (1995) (2)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV (2019) (2)
- Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance (2018) (2)
- SLCO Transport Genes in Prostate Cancer—Letter (2011) (2)
- Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure (2016) (2)
- Antiangiogenesis in prostate cancer (2004) (2)
- Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. (2022) (2)
- A Randomized Phase II Trial of Thalidomide , an Angiogenesis Inhibitor , in Patients with Androgen-independent Prostate Cancer 1 (2001) (2)
- Abstract 14: Preclinical evaluation of novel HIF-1α/P300 binding inhibitors (2018) (1)
- DPYD Testing: Time to Put Patient Safety First. (2023) (1)
- Epidemiology of drug interactions in cancer patients (2006) (1)
- OA11.05 Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer (2021) (1)
- A pharmacokinetically guided phase II study of CAI in androgen-independent prostate cancer (1999) (1)
- A Phase 1 Study of TRC 102 , An Inhibitor of Base Excision Repair , and Pemetrexed in Patients with Advanced Solid Tumors (2017) (1)
- Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results. (2015) (1)
- Single whole genome sequencing analysis blazes the trail for precision medicine (2022) (1)
- Androgen receptor splice variant 7 (AR‐V7) and AR full‐length (AR‐FL) as predictive biomarkers of therapeutic resistance: partners in crime? (2019) (1)
- UGT1A1 Polymorphisms and Mutations Affect Anticancer Drug Therapy (2020) (1)
- Preformulation Study of NSC-726796 (2012) (1)
- Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer. (2015) (1)
- 423: Evaluation of the Endostatin Polymorphism D104N in Prostate Cancer (2004) (1)
- PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials. (2022) (1)
- A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies 1 (2001) (1)
- Tumor regression and growth rates determined in two intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. (2012) (1)
- A genomic strategy for predicting androgen receptor activity in prostate tumors (2009) (1)
- A Pharmacokinetic (PK) study of SU-5416 in patients on enzyme-inducing anti-epileptic drugs (EIAED), by the North American Brain Tumor Consortium (2004) (1)
- Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. (2020) (1)
- Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib. (2013) (1)
- Genetic variant associated with aggressive not indolent prostate cancer (2010) (1)
- Factors affecting the pharmacokinetic profile of MS-275, a histone deacetylase inhibitor, in humans (2005) (1)
- Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer. (2022) (1)
- Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. (2004) (1)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. (2020) (1)
- Advances in Brief Hyperinducibility of Hypoxia-responsive Genes without p 53 / p 21-dependent Checkpoint in Aggressive Prostate Cancer 1 (2000) (1)
- Expanding the use of abiraterone in prostate cancer: Is earlier always better? (2018) (1)
- Local and Systemic Antitumor Effects of Photo‐activatable Paclitaxel Prodrug on Rat Breast Tumor Models (2019) (1)
- Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact. (2016) (1)
- Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (2014) (1)
- Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report (1999) (1)
- Population Pharmacokinetics of UCN-01 (2013) (1)
- Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. (2013) (1)
- Antineoplastons: when is enough enough? (2018) (1)
- A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC). (2021) (1)
- Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. (2010) (1)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (1)
- Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome (2022) (1)
- Recent Advances in Angiogenesis Drug Development (2008) (1)
- Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (1)
- Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup (1999) (1)
- A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies. (2021) (1)
- Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC). (2017) (1)
- Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy. (2019) (1)
- Thalidomide and Analogs (2010) (1)
- Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228 (2008) (1)
- Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer. (2021) (1)
- Androgen receptor and HIF-1α interaction in prostate cancer. (2012) (1)
- Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma (2019) (1)
- Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability. (2018) (1)
- Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC). (2021) (1)
- Temporal-Mediated FGFR1 independence: Implications for targeting candidate molecules in prostate cancer (2008) (1)
- A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. (2013) (1)
- inhibitor, in adults with refractory and relapsed acute leukemias Phase 1 and pharmacologic study of MS-275, a histone deacetylase (2013) (1)
- Chemoprevention in Prostate Cancer (2006) (1)
- First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (2023) (1)
- The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years? (2021) (1)
- A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib. (2014) (1)
- 823PExpression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer (2017) (1)
- The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study. (2022) (1)
- PCM-10PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF 5-AZACYTIDINE FOLLOWING INTRAVENOUS, INTRANASAL, AND INTRATHECAL ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL (2016) (1)
- Alemtuzumab clearance, lymphocyte count, and T‐cell chimerism after hematopoietic stem cell transplant in sickle cell disease (2021) (1)
- Book Review: Oxford Textbook of Clinical Pharmacology and Drug Therapy. 2nd Edition (1993) (1)
- PHRM-03. CEREBROSPINAL FLUID PENETRATION OF PEXIDARTINIB (PLX3397), A CSF1R INHIBITOR, IN A NONHUMAN PRIMATE MODEL (2018) (1)
- Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier (2017) (1)
- Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer (2014) (1)
- Phenylacetate Pharmacokinetics Based on Iterative Two‐Stage Population Analysis (2001) (1)
- Seminar article The use of thalidomide in androgen-independent prostate cancer (2006) (1)
- A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. (2022) (1)
- Facebook groups for alternative treatments for cancer: advertising masquerading as community support. (2021) (1)
- The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma (2018) (1)
- Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma (2020) (1)
- Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism (2010) (1)
- 643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans (2020) (1)
- 2259 Tremelimumab - A monoclonal antibody against CTLA-4 - in combination with local tumor ablation (TACE or RFA) in patients with hepatocellular carcinoma (HCC) (2015) (1)
- Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics (2018) (1)
- Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques (Macaca mulatta) Based on the Pharmacokinetics of Intrathecally Administered Inulin. (2020) (1)
- EPCT-16. LENALIDOMIDE ACTIVITY IN PILOCYTIC ASTROCYTOMA AND OPTIC PATHWAY GLIOMAS: REPORT ON CHILDREN’S ONCOLOGY GROUP ACNS1022 (2021) (1)
- Polypharmacy in View of Advances in Cancer Treatment (2008) (1)
- Androgen receptor modulation: Lessons learned from beyond the prostate (2007) (1)
- Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer (2017) (1)
- Abstract 5480: Effects of UGT1A1 genotype on pharmacokinetics and toxicities of belinostat administered by continuous infusion in two clinical trials (2015) (1)
- Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance (2015) (1)
- Abstract 1274: Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial (2017) (0)
- Abstract 2048: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion (2016) (0)
- APhase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous SystemTumors (2007) (0)
- Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model. (2012) (0)
- Sifting Through the Multitude of Novel Therapies for Prostate Cancer (2006) (0)
- Mapping a path for cancer precision medicine (2017) (0)
- O-004 Targeting the epigenome for lung cancer therapy (2005) (0)
- UGT1A1 genotype effects on PK, PD and toxicities of belinostat administered by 48 h continuous infusion. (2015) (0)
- Abstract 1863: Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial (2014) (0)
- A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC). (2015) (0)
- Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer (2007) (0)
- Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32. (2018) (0)
- Baricitinib for Refractory Chronic Graft-Versus-Host Disease (cGVHD): Results of a Phase 1/2 Study (2023) (0)
- 1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC) (2022) (0)
- Investigating Ras-dependent cancer (2009) (0)
- Circulating endothelial cells as a therapeutic marker for docetaxel treatment and combination therapy of docetaxel and thalidomide in a human prostate cancer model (2006) (0)
- PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC). (2022) (0)
- Club A New Predictive Tool for Postoperative Radiotherapy in Prostate Cancer (2017) (0)
- Determination of Metarrestin (ML-246) in Human Plasma for a First-in-Human Clinical Pharmacokinetic Application by a Simple and Efficient UHPLC-MS/MS Assay (2023) (0)
- Even more cost savings? (2006) (0)
- Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects (2014) (0)
- A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV. (2018) (0)
- A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities (2022) (0)
- YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: “Hippo-thetical”, new therapeutic targets? (2016) (0)
- Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors (2022) (0)
- Abstract 5379: Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer (2012) (0)
- Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial (2015) (0)
- Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). (2023) (0)
- Abstract LB-350: Tissue and serum miRNA profiling for detection of bladder, breast and prostate cancer (2011) (0)
- Development of a CYP1B1*3 genotyping assay and mechanism of action studies related to docetaxel treatment in CRPC. (2014) (0)
- Abstract 2331: Select epidithiodiketopiperazine (ETP) compounds disrupt the HIF-1α/p300 interaction and HIF-mediated transcription (2012) (0)
- Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular carcinoma (HCC) (2014) (0)
- P A polymorphism in the promoter of the FRAS 1 gene is associated with metastatic prostate cancer (2017) (0)
- Abstract 2943: Severe hepatotoxicity of mithramycin therapy caused by altering expression of hepatocellular bile transporters (2019) (0)
- New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer (2015) (0)
- Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (0)
- Abstract 1848: Expression of an androgen transporter, organic anion transporting polypeptide 1B3, impacts progression and treatment of prostate cancer (2012) (0)
- Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer (2010) (0)
- Commentary: Electronic Nicotine Delivery Systems (2022) (0)
- Antiandrogens in the 21st century (2009) (0)
- 21 Pharmacogenomics of mithramycin in thoracic malignancies (2014) (0)
- Chapter 12 Current management of hormone-refractory prostate cancer (1999) (0)
- Phase I I T rial o f T halidomide a nd C armustine f or P atients With R ecurrent H igh-Grade G liomas (2003) (0)
- 978: A Phase II Trial of Docetaxel, Thalidomide and Estramustine in Metastatic Androgen-Independent Prostate Cancer (2006) (0)
- Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer. (2023) (0)
- A promising cancer target: lead compounds blocking the HIF-1alpha/p300 interaction (2008) (0)
- Single oral dose pharmacokinetics (PK) and safety of 2-methoxyestradiol (2ME2) in patients with solid tumors (2005) (0)
- Comprar Drug Management Of Prostate Cancer | Figg, William D. | 9781603278317 | Springer (2010) (0)
- A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors. (2014) (0)
- Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel (2022) (0)
- Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted (2022) (0)
- Assessing progress against prostate cancer. (2006) (0)
- Cancer Therapy: Clinical A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer (2011) (0)
- Phase I/II study of the safety, pharmacokinetics, and efficacy of pomalidomide in the treatment of Kaposi sarcoma in individuals with or without HIV. (2013) (0)
- Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer. (2019) (0)
- Thalidomide : National Cancer Institute, National Institutes o f Health, Bethesda, Maryland (1999) (0)
- Abstract OT-26-03: Racial disparities inCYP3Avariants in the metabolism of ribociclib in breast cancer patients (2021) (0)
- A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114). (2021) (0)
- Cabazitaxel (2010) (0)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (0)
- Disruption of the HIF‐1α/p300 interaction as a means of inhibiting angiogenesis (2012) (0)
- Abstract 366: Translational modeling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant prostate cancer: predicting clinical response using preclinical data (2014) (0)
- Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites following Hepatic Drug Eluting Chemoembolization (2019) (0)
- Abstract 2206: Molecular interaction of HIF-1α and the androgen receptor in prostate cancer (2012) (0)
- Abstract 3095: The molecular, cellular, and physiological consequences of disrupting the HIF-1α interaction (2011) (0)
- Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion (2019) (0)
- Detection of bladder, breast and prostate cancer using serum and tissue miRNA profiling (2011) (0)
- EXTH-100. EVALUATION OF PANOBINOSTAT PLASMA AND CEREBROSPINAL FLUID (CSF) PHARMACOKINETIC PROFILE FOLLOWING ADMINISTRATION OF THE CAPSULE FORMULATION FARYDAK® IN A NON-HUMAN (NHP) PRIMATE PRECLINICAL MODEL (2022) (0)
- Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer. (2023) (0)
- ACTR-85. THE EFFECT OF REGADENOSON ON TEMOZOLOMIDE NEUROPHARMACOKINETICS IN GLIOBLASTOMA PATIENTS MEASURED BY INTRACEREBRAL MICRODIALYSIS (2017) (0)
- Novel multi-component approaches towards dimeric epidithiodiketopiperazines as anti-cancer agents (2011) (0)
- Phase I I T rial o f t he A ntiangiogenic A gent T halidomide i n Patients W ith R ecurrent H igh-Grade G liomas (2000) (0)
- A Polymorphic Variant of AFAP-110 Enhances (2010) (0)
- A simple and rapid UHPLC–MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH‐1473759 in murine plasma (2017) (0)
- Nitrate Tolerance: Does Tid Isosorbide Dinitrate Mean Dosing Every Eight Hours? (1991) (0)
- DEVELOPMENT OF ANGIOGENESIS INHIBITORS FOR THE TREATMENT OF CANCER (2008) (0)
- Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. (2023) (0)
- MOLECULAR CANCER THERAPEUTICS | TARGETING DRUG RESISTANCE Vertical Inhibition of the RAF–MEK–ERKCascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Mutant Rhabdomyosarcoma (2021) (0)
- Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group. (2023) (0)
- Abstract 32: Analysis of Serum Clopidogrel Active Metabolite Concentration Identifies Novel Genetic Variants Associated With Clopidogrel Pharmacokinetics (2016) (0)
- Combinatorial anti-leukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide CPS49 and flavopiridol. (2008) (0)
- 642 Organic anion transporting polypeptides contribute to prostate cancer progression (2010) (0)
- A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma. (2022) (0)
- A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea (2022) (0)
- Erratum: Survivin is not induced by novel taxanes (Molecular Pharmaceutics (2010) 7: 6 (2216-2223)) (2011) (0)
- A pharmacokinetic study of Genetaxyl (G) together with cyclosporin A (CsA) administered orally in cancer patients. (2006) (0)
- Abstract B29: A meta-analysis of racial disparities in the association between 8q24 and prostate cancer risk (2012) (0)
- A phase II clinical trial of sorafenib in androgen-independent prostate cancer: Characterization of pharmacokinetics (2007) (0)
- ET-30A PHASE I TRIAL OF AZD7451, A TROPOMYOSIN-RECEPTOR KINASE (TRK) INHIBITOR, FOR ADULTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) (2014) (0)
- Preformulation Study of NSC-726796 (2012) (0)
- Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. (2023) (0)
- Comment: Ranitidine Does Not Inhibit Theophylline Metabolism (1991) (0)
- Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation (2021) (0)
- Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial (2023) (0)
- How do you take your coffee? (2019) (0)
- Comparative in vitro properties and pharmacokinetics of paclitaxel following the administration of Taxol and Paxene (2005) (0)
- A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy (2021) (0)
- Abstract A069: Mechanisms governing the transcriptional regulation of the liver-specific transporter OATP1B3 in prostate cancer (2019) (0)
- Imatinib mesylate for the treatment of sclerotic skin chronic graft-versus-host disease (2012) (0)
- Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (2023) (0)
- 398 Development of an LC/MS/MS method for the quantitative determination of the Akt inhibitor PIA5 in mouse plasma (2004) (0)
- EXTH-25. THE CSF PENETRATION OF THE PROCASPASE-ACTIVATING COMPOUND (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN A NONHUMAN PRIMATE CSF ACCESS MODEL (2020) (0)
- MolecularAlterations in Primary Prostate Cancer afterAndrogen Ablation Therapy (2005) (0)
- A Phase 2 Study of Seviteronel (INO-464) in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Enzalutamide Treatment (2020) (0)
- DNA microarrays: Tissue removal and processing affects gene expression (2006) (0)
- Abstract 3766: Correlating locus-specific changes in histone trimethylation and gene expression in hypoxia (2022) (0)
- Abstract B29: A critical role of the SUMO pathway in KRAS-driven oncogenesis (2014) (0)
- Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma (2009) (0)
- Systems Seeing Through the Clouds (2022) (0)
- Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes (2023) (0)
- Genetic predisposition to oral absorption of imatinib: Correlation of a variant allele in ABCG2 with transport activity (2005) (0)
- Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system (2017) (0)
- Abstract B28: Organic anion transporting polypeptide 1B3 as a novel biomarker for hypoxia in prostate cancer. (2011) (0)
- 1 CPS 49-induced neurotoxicity does not cause limb patterning anomalies in 2 developing chicken embryos 3 4 5 6 (2017) (0)
- Urological Survey: Abstracts: Benign and Malignant Neoplasms of ProstateEffect of Prednisone on Prostate-Specific Antigen in Patients With Hormone-Refractory Prostate Cancer (1999) (0)
- Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population (2018) (0)
- Exploratory covariate analysis for phase II clinical trial of sorafenib (S) in metastatic castrate-resistant prostate cancer (mCRPC) (2008) (0)
- Subcutaneous Atezolizumab: A Jab Without a Benefit (2021) (0)
- Book Review: Handbook of Pharmaceutical Biotechnology (2004) (0)
- Percutaneous Hepatic Perfusion (Chemosat® or CS-PHP) of Melphalan in Patients (PTS) with Hepatic Metastases from Melanoma: Phase III Pharmacokinetic Analysis (2012) (0)
- Predictive Biomarkers and Personalized Medicine Impact of ABCB 1 Allelic Variants on QTc Interval Prolongation (2011) (0)
- Isolation and identification of novel natural products that inhibit P300/HIF-1α interaction (2015) (0)
- Androgen receptor and HIF-1α interaction in prostate cancer. (2012) (0)
- EXPLOITING COVID-19: QUACK-A-MOLE (2020) (0)
- Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance. (2022) (0)
- SCDT-32. THERAPEUTIC USE OF VEGF IN BLOOD-BRAIN BARRIER MODULATION (2017) (0)
- Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application. (2022) (0)
- EXTH-65. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS COMPARISON OF BRAF AND MEK INHIBITORS FOLLOWING SINGLE AND EXTENDED ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL (2019) (0)
- Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs (2022) (0)
- An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC). (2016) (0)
- Abstract 4535: Thalidomide inhibits the TGFβ-mediated synthesis of testosterone from DHEA in prostate cancer (2011) (0)
- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer (2010) (0)
- Abstract 2043: Effects of 24-h carboplatin pretreatment on olaparib clearance in women's cancers using noncompartmental and population pharmacokinetic analyses (2016) (0)
- Evidence Regarding Pharmacogenetics in Pain Management and Cancer (2023) (0)
- EXTH-64. COMPARISON OF PANOBINOSTAT CSF PENETRATION WITH CNS PENETRATION FOLLOWING SYSTEMIC ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL (2021) (0)
- Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response (2015) (0)
- Abstract 1794: Identification of novel single nucleotide polymorphisms (SNPs) associated with risk and prognosis in patients with castration-resistant prostate cancer (CRPC) (2016) (0)
- A new predictive tool for postoperative radiotherapy in prostate cancer (2017) (0)
- In Silico Re-Optimization of Atezolizumab Dosing using Population Pharmacokinetic and Exposure-Response Simulation. (2023) (0)
- Phenotypic approach to drug discovery (2009) (0)
- EPCT-09. CNS LEVELS OF PANOBINOSTAT IN A NON-HUMAN PRIMATE MODEL: COMPARISON OF BLOOD AND CEREBROSPINAL FLUID PHARMACOKINETIC METHODS AND MALDI MSI (2021) (0)
- EXTH-02. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF 5-AZACYTIDINE ALONE AND IN COMBINATION WITH INULIN IN A NON-HUMAN PRIMATE MODEL (2017) (0)
- Reviewing the role of healthy volunteer studies in drug development (2018) (0)
- TMIC-19. ASTROCYTIC S1P3 SIGNALING MODULATES BLOOD-TUMOR BARRIER PERMEABILITY IN BRAIN METASTASES (2017) (0)
- Book Review: Principies of Antineoplastic Drug Development and Pharmacology (1997) (0)
- A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. (2022) (0)
- Challenges in overcoming hormonal resistance in prostate cancer (2014) (0)
- Book Review: Management of Prostate Cancer, 2nd Edition (2005) (0)
- Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer (2023) (0)
- Highlights of the 9th NCI-EORTC Meeting (1996) (0)
- Books Received (2005) (0)
- Ibrutinib-Associated Sudden Death in Patients with CLL (2022) (0)
- Detectible mosaic truncating PPM1D mutations, age and breast cancer risk (2019) (0)
- Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia (2022) (0)
- Review Articles IN VIVO MODELS OF PROSTATE CANCER METASTASIS TO BONE (2005) (0)
- EXTH-102. PLASMA AND CEREBROSPINAL FLUID (CSF) PHARMACOKINETICS (PK) OF MIRDAMETINIB IN A NON-HUMAN PRIMATE (NHP) MODEL (2022) (0)
- 605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide (2021) (0)
- Effect of thalidomide on the TGFβ-1-mediated synthesis of testosterone from DHEA in prostate cancer. (2012) (0)
- Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma (2022) (0)
- PHRM-01. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE DNA HYPOMETHYLATING AGENT, GUADECITABINE (SGI-110), FOLLOWING SUBCUTANEOUS ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL (2018) (0)
- Gene expression analysis enables repositioning of mithramycin for precision medicine inhibition of cancer stem cell signaling in thoracic malignancies (2015) (0)
- Tumor growth rate constants derived from data gathered while patients are on clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data (2007) (0)
- A Chiral Pool Approach Toward the Synthesis of Thalidomide Metabolites. (2007) (0)
- A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer 1 (2006) (0)
- The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. (2022) (0)
- Targeting the metastatic niche: Single-cell lineage tracing in prime time (2023) (0)
- Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues. (2004) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- Resisting resistance: Establishing new treatment options for CRPC patients (2016) (0)
- Development of Thalidomide and Its IMiD Derivatives (2008) (0)
- DIPG-27. OPTIMIZING CLINICAL TRIAL DESIGN: PHARMACOKINETICS OF MARIZOMIB AND PANOBINOSTAT IN A NON-HUMAN PRIMATE MODEL (2019) (0)
- Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndrome (2022) (0)
- Impact of lenalidomide on the antiproliferative effect of gemcitabine/carboplatin (GC) and gemcitabine/cisplatin (GP) against urothelial carcinoma (UC) cells in vitro. (2011) (0)
- Commentary: “Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry” (2020) (0)
- Abstract 4330: Astrocytic S1P3 regulates blood-brain/tumor barrier permeability (2017) (0)
- Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers (2021) (0)
- Nelfinavir , ALeadHIVProtease Inhibitor , Is aBroad-Spectrum , AnticancerAgent that InducesEndoplasmicReticulum Stress , Autophagy , andApoptosis Invitro and Invivo (2007) (0)
- 395: Leukapheresis of Patients with Androgen Independent Prostate Cancer (AIPC) May Enhance in Vitro Isolation of Prostate Cancer Cells (2004) (0)
- Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients (2007) (0)
- Pharmacogenetics of organic anion transporting peptides (OATP): An association of a SLCO1B3 polymorphism with the overall survival in white Caucasian patients with androgen independent prostate cancer (2007) (0)
- OP059: Clinical impact of a targeted pharmacogenomic assessment within a cohort of individuals with suspected inborn errors of immunity (2022) (0)
- Phase I C linical T rial o f O ral C OL-3, a M atrix Metalloproteinas e I nhibitor, i n P atients W ith R efractory Metastatic C ancer (2001) (0)
- Abstract IA023: Therapeutic efficacy of trametinib and ganitumab in RAS-mutated rhabdomyosarcoma (2022) (0)
- Abstract 2546: Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer (2014) (0)
- Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD) (2012) (0)
- Phase II Tria l o f the Ant iangiogenic Agent Thal idomide in Pat ients With Recurrent High-Grade Gl iomas (2000) (0)
- Racial variations in pharmacogenetics that impact treatment outcomes (2007) (0)
- HIF Prolyl Hydroxylase 2 (PHD2/EGLN1) in Complex with 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (Molidustat) (2021) (0)
- Prostate cancer - 6th International Congress. (2006) (0)
- Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa. (2020) (0)
- Abstract CT058: A phase 2 open-label study to evaluate the efficacy and safety of VT-464 in patients with androgen receptor positive triple-negative breast cancer patients, and men with ER positive breast cancer (2017) (0)
- Abstract 2340: CPS49 and Flavopiridol: a new selective drug combination for advanced prostate cancer (2012) (0)
- HIF Prolyl Hydroxylase 2 (PHD2/EGLN1) in complex with tert-butyl 6-(5-hydroxy-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-1-yl)nicotinate (IOX4) (2021) (0)
- Association between variants on 8q24 and prostate cancer: A review and meta-analysis. (2012) (0)
- Role of CYP3A4 phenotyping by midazolam clearance in predicting irinotecan pharmacokinetics. (2004) (0)
- Analogs of thalidomide as inhibitors of angiogenesis. (2002) (0)
- Abstract CT222: Differences in pharmacokinetics of TRC105 (anti-endoglin antibody) when administered as a single agent versus in combination with bevacizumab (Bev) (2014) (0)
- A polymorphism in a transporter of testosterone as a determinant of androgen independence in prostate cancer (2008) (0)
- Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC). (2016) (0)
- Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients. (2012) (0)
- Association between variants on 8q24 and prostate cancer: A review and meta-analysis. (2012) (0)
- A pharmacogenetic study of docetaxel and thalidomide in patients with androgen-independent prostate cancer (AIPC) using targeted human DMET genotyping platform (2007) (0)
- Erratum: Hormonal therapy for prostate cancer (The Journal of Urology 173, 5 (1567)) (2005) (0)
- Abstract P1-01-01: The blood-Tumor barrier as a therapeutic target to improve therapy of brain metastases of breast cancer (2018) (0)
- Urinary-activated HGF as a noninvasive biomarker for the diagnosis of prostate cancer. (2011) (0)
- Erratum to: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-independent Prostate Cancer. (2016) (0)
- Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression. (2020) (0)
- UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity (2013) (0)
- Are we making an impact on prostate cancer? (1999) (0)
- 520 Modulation of N,N-dimethylamino-benzoylphenylurea (BPU) absorption by the CYP3A and ABCG2 inhibitor ritonavir (2004) (0)
- Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer. (2023) (0)
- Urinary vascular endothelial growth factor (VEGF) levels and trends in cancer patients (2003) (0)
- A phase I dose expansion cohort study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509). (2017) (0)
- Evaluation of variants of the rs1934951 locus of CYP2C8 and bisphosphonate-related osteonecrosis of the jaw in castrate-resistant prostate cancer (CRPC) patients. (2010) (0)
- Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT (2020) (0)
- TreatmentWith Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in PatientsWith Smoldering or Newly DiagnosedMultipleMyeloma (2015) (0)
- Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation (2020) (0)
- Effect of thalidomide on the TGFβ-1-mediated synthesis of testosterone from DHEA in prostate cancer. (2012) (0)
- A Facile Scheme for Phthalimide Phthalimidine Conversion. (1999) (0)
- Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases (2018) (0)
This paper list is powered by the following services:
Other Resources About William Douglas Figg Sr.
What Schools Are Affiliated With William Douglas Figg Sr.?
William Douglas Figg Sr. is affiliated with the following schools:
- Consorzio ICoN
- University of Oxford
- Columbia University
- University of Arkansas
- McGill University
- James Cook University
- Newcastle University
- University of British Columbia
- University of Louisville
- Virginia Commonwealth University
- Michigan State University
- Case Western Reserve University
- University of Pittsburgh
- University of Bonn
- Harvard University
